Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ)

Currently no specific biomarkers exist for the screening of pregnancies at risk for Down syndrome (DS). Since a quantitative proteomic approach with isobaric labelling (iTRAQ) has recently been suggested to be highly suitable for the discovery of novel plasma biomarkers, we have now used this method...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Biomedicine & Biotechnology pp. 952047 - 952048
Autores principales: Kolla V, Jenö P, Moes S, Tercanli S, Lapaire O, Choolani M, Hahn S
Formato: Journal Article
Publicado: Wiley-Blackwell 2010
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105082086&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105082086
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11107243
        137K
      jtl: Journal of Biomedicine & Biotechnology
      issn: 11107243
      maglogo: N
    pubinfo:
      dt: 2010
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        105082086
        2010748327
        NLM19902006
        PMC2774473
        105082086
      ppf: 952047
      ppct: 1
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ)
      aug:
        au:
          Kolla V
          Jenö P
          Moes S
          Tercanli S
          Lapaire O
          Choolani M
          Hahn S
        affil: Department of Biomedicine, University Women's Hospital, 4031 Basel, Switzerland.
      sug:
        subj:
          Down Syndrome Blood
          Down Syndrome Diagnosis
          Isotopes
          Prenatal Diagnosis Methods
          Proteomics Methods
          Adult
          Biological Markers Blood
          Biochemical Phenomena
          Female
          Fetal Diseases Diagnosis
          Indicators and Reagents
          Mass Spectrometry
          Metabolic Networks and Pathways
          Pregnancy
          Proteins Analysis
          Proteins
          Software
          Adult: 19-44 years
          Female
      ab: Currently no specific biomarkers exist for the screening of pregnancies at risk for Down syndrome (DS). Since a quantitative proteomic approach with isobaric labelling (iTRAQ) has recently been suggested to be highly suitable for the discovery of novel plasma biomarkers, we have now used this method to examine for potential quantitative changes in the plasma proteome of the pregnancies bearing DS fetuses in comparison to normal healthy babies. In our study, we used plasma from six women with DS pregnancies and six with uncomplicated pregnancies care were taken to match cases and controls for gestational and maternal age, as these could be a confounder. In our quantitative proteomics analysis we were able to detect 178 proteins using iTRAQ labelling in conjunction with 4800 MALDI TOF/TOF. Amongst these we observed changes in betaHCG, a known screening marker for DS, indicating that our assay was functional. We found a number of elevated proteins Ig lambda chain C region, serum amyloid P-component, amyloid beta A4, and under expressed proteins like gamma-actin and titin in DS pregnancies. These proteins are also found in the sera of patients with Alzheimer disease, which share similar pathologies of DS. Our study therefore indicates that the iTRAQ labelling approach may be indeed useful for the detection of novel biomarkers.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N